ABT
A smaller target, same old handshake
UBS just did the classic Wall Street move: trim the target, keep the thumbs-up. The bank cut Abbott Laboratories’ price target to $135 from $158 while sticking with a Buy rating, which is basically analyst code for: “We still like the story, we just don’t think it gets there as fast anymore.”
Why you should care
For investors, this matters because Abbott has been getting whacked from a bunch of directions lately — mixed Q1 results, softer guidance, and a parade of analysts dialing back their expectations. UBS is now the latest to say the ride might not be as breezy as hoped, even if the destination still looks decent.
The Street is still on team Abbott, just less aggressively
This isn’t a full-on breakup. It’s more like your friend saying they still believe in your marathon training, but maybe not the “I’ll be qualified by next Tuesday” part.
What’s happening around Abbott right now:
- Analysts have been trimming targets across the board
- The company’s recent earnings/guidance combo left investors a little squinty-eyed
- Abbott’s newer growth drivers, like diabetes and diagnostics, are still part of the bull case
Big picture
When a stock gets multiple target cuts in a short span, it usually means the market is re-pricing reality, not abandoning the name. Abbott still has plenty of believers — they’re just pulling in their horns a bit. That can pressure the stock near term, even if the long-term thesis still has legs.